Literature DB >> 20851250

Costs of eliminating HIV in South Africa have been underestimated.

Bradley Wagner, Sally Blower.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20851250     DOI： 10.1016/S0140-6736(10)61442-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  13 in total

1.  Sexual HIV transmission and antiretroviral therapy: a prospective cohort study of behavioral risk factors among men and women living with HIV/AIDS.

Authors:  Seth C Kalichman; Chauncey Cherry; Denise White; Miche'l Jones; Tamar Grebler; Moira O Kalichman; Mervi Detorio; Angela M Caliendo; Raymond F Schinazi
Journal:  Ann Behav Med       Date:  2011-08

2.  Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs.

Authors:  Ravindra K Gupta; Mark A Wainberg; Francoise Brun-Vezinet; Jose M Gatell; Jan Albert; Anders Sönnerborg; Jean B Nachega
Journal:  J Infect Dis       Date:  2013-06-15       Impact factor: 5.226

3.  Economics of antiretroviral treatment vs. circumcision for HIV prevention.

Authors:  Till Bärnighausen; David E Bloom; Salal Humair
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-06       Impact factor: 11.205

Review 4.  AIDS vaccines and preexposure prophylaxis: is synergy possible?

Authors:  Jean-Louis Excler; Wasima Rida; Frances Priddy; Jill Gilmour; Adrian B McDermott; Anatoli Kamali; Omu Anzala; Gaudensia Mutua; Eduard J Sanders; Wayne Koff; Seth Berkley; Patricia Fast
Journal:  AIDS Res Hum Retroviruses       Date:  2010-12-16       Impact factor: 2.205

Review 5.  Harnessing the prevention benefits of antiretroviral therapy to address HIV and tuberculosis.

Authors:  Reuben Granich; Ying-Ru Lo; Amitabh B Suthar; Marco Vitoria; Rachel Baggaley; Carla Makhlouf Obermeyer; Craig McClure; Yves Souteyrand; Jos Perriens; James G Kahn; Rod Bennett; Caoimhe Smyth; Brian Williams; Julio Montaner; Gottfried Hirnschall
Journal:  Curr HIV Res       Date:  2011-09       Impact factor: 1.581

Review 6.  Universal testing and treatment as an HIV prevention strategy: research questions and methods.

Authors:  Richard Hayes; Kalpana Sabapathy; Sarah Fidler
Journal:  Curr HIV Res       Date:  2011-09       Impact factor: 1.581

7.  Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006.

Authors:  Eduard J Beck; Sundhiya Mandalia; Gary Lo; Peter Sharott; Mike Youle; Jane Anderson; Guy Baily; Ray Brettle; Martin Fisher; Mark Gompels; George Kinghorn; Margaret Johnson; Brendan McCarron; Anton Pozniak; Alan Tang; John Walsh; David White; Ian Williams; Brian Gazzard
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

8.  HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions.

Authors:  Gesine Meyer-Rath; Mead Over
Journal:  PLoS Med       Date:  2012-07-10       Impact factor: 11.069

9.  Universal access to HIV treatment versus universal 'test and treat': transmission, drug resistance & treatment costs.

Authors:  Bradley G Wagner; Sally Blower
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

Review 10.  Combination prevention: new hope for stopping the epidemic.

Authors:  Sten H Vermund; Richard J Hayes
Journal:  Curr HIV/AIDS Rep       Date:  2013-06       Impact factor: 5.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.